GlobeNewswire·Nov 13, 2026, 4:05 PM ET

Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update

VTGN

Vistagen reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, & provided a corporate update on its fasedienol pipeline.
The company received constructive FDA feedback regarding Phase 3 development of fasedienol for social anxiety disorder, including recommendations to use the Liebowitz Social Anxiety Scale (LSAS) as the primary endpoint.
Based on FDA feedback, Vistagen plans to focus future Phase 3 studies on the overall treatment of social anxiety disorder rather than just acute treatment.
Preliminary positive data from the open-label extension of the PALISADE-4 Phase 3 study showed clinically relevant improvement in social anxiety over four months.
Douglas J. Williamson, MD, was appointed to the Board of Directors, adding extensive neuroscience drug development experience.
Vistagen implemented cost-management initiatives to prioritize capital allocation across clinical-stage programs & extend its operating runway.
Research and development expenses decreased to $6.6 million for the quarter ended September 30, 2026, from $15.9 million in the prior year period due to lower clinical development costs.
General and administrative expenses increased slightly to $4.5 million for the quarter, driven by higher legal fees & consulting costs.
The company reported a net loss of $10.7 million for the quarter, compared to $19.4 million in the same period last year.
Cash, cash equivalents, & marketable securities totaled $20.0 million as of September 30, 2026, sufficient to fund operations into 2026 but not expected to extend the cash runway beyond one year.

Company: Vistagen Therapeutics, Inc.
Keywords: Nasdaq:VTGN, Vistagen Therapeutics, Inc.